原发性血小板增多症 中国就医指南

Essential Thrombocythemia (ET) is a chronic myeloproliferative neoplasm characterized by sustained overproduction of platelets (thrombocytes) in the bone marrow, independent of physiological stimuli such as inflammation or bleeding. Unlike reactive thrombocytosis, ET arises from clonal hematopoietic stem cell mutations—most commonly in the JAK2 V617F gene (present in ~55–60% of cases), followed by CALR (~25–30%) and MPL (~3–5%) mutations. These driver mutations constitutively activate the JAK-STAT signaling pathway, leading to unchecked megakaryocyte proliferation and platelet release. The disease is typically indolent but carries significant long-term risks: arterial and venous thrombosis (e.g., stroke, myocardial infarction, deep vein thrombosis), microvascular disturbances (headache, erythromelalgia, transient ischemic attacks), and, less commonly, progression to myelofibrosis or acute myeloid leukemia (<2% per decade). Epidemiologically, ET has an annual incidence of approximately 0.5–2.5 per 100,000 persons, with median age at diagnosis around 60 years; it is slightly more common in women (female-to-male ratio ~1.5:1). While rare in children and adolescents, ET can occur across adulthood. Known risk factors include advancing age (>60 years), prior thrombotic history, JAK2 mutation status (associated with higher thrombotic risk), and cardiovascular comorbidities (e.g., hypertension, diabetes, smoking). Notably, leukocytosis and extreme thrombocytosis (>1,500 × 10⁹/L) may further elevate thrombotic risk. Quality of life in ET patients is frequently compromised—not solely by physical symptoms like fatigue, lightheadedness, visual disturbances, or burning pain in hands and feet—but also by psychological burden: anxiety about clotting events, uncertainty regarding disease progression, treatment side effects (e.g., hydroxyurea-induced skin changes or cytopenias), and lifelong monitoring requirements. Many patients report reduced work capacity, sleep disruption, and diminished social engagement. Importantly, ET is not curable with conventional therapy, but risk-adapted management significantly improves survival and reduces morbidity. Low-risk patients (age <60, no prior thrombosis, no high-risk mutations) often require only observation or low-dose aspirin; high-risk patients benefit from cytoreductive therapy (e.g., hydroxyurea, interferon-alpha, or anagrelide) to maintain platelet counts <400 × 10⁹/L and mitigate thrombotic complications. Regular hematologic follow-up—including complete blood counts, molecular testing, and bone marrow evaluation when indicated—is essential for timely intervention and personalized care.

# 原发性血小板增多症（ET）治疗方案与费用明细（血液科）

一、非手术/保守治疗（一线首选，适用于低危及无症状患者）

• •适用人群：年龄＜60岁、无血栓/出血史、JAK2野生型、PLT＜1500×10⁹/L
• •方案：阿司匹林（75–100 mg/d）+ 观察随访
• •年费用区间：

- 检查费（每3–6个月）：血常规+外周血涂片+JAK2/CALR/MPL基因检测+LDH+肝肾功能 = 480–950元

二、药物治疗（中高危或需降板者）

• •羟基脲（一线细胞减数药）：年费用 1,200–2,600元（含药费+每月血常规+肝功监测）
• •干扰素α-2b（年轻/育龄/妊娠期优选）：年费用 38,000–65,000元（含皮下注射剂+骨髓穿刺复查）
• •阿那格雷（难治性心动过速/微循环障碍者）：年费用 72,000–95,000元

三、核心介入/根治性方案（仅限继发严重并发症）

• •无根治性手术：ET为克隆性造血干细胞疾病，不适用手术切除或干细胞移植作为常规治疗；异基因造血干细胞移植仅用于极少数进展为MF/AML的终末期患者（＜5%），全周期费用 45–75万元（含预处理、移植、ICU及抗排异治疗）

四、特殊复杂情况处理

• •耐药/进展为骨髓纤维化：芦可替尼靶向治疗，年费用 18–22万元（医保谈判后自付约3–5万元）
• •急性血栓事件（如脑梗/肠系膜动脉栓塞）：急诊抗凝+血小板单采术（单次 4,200–6,800元）

方案快速选择指南

• •预算＜2,000元/年：阿司匹林+规律随访（低危者首选）
• •预算1万–5万元/年：羟基脲规范治疗（中高危主力方案）
• •育龄/年轻患者：优先干扰素α（兼顾疗效与生育安全）
• •进展为MF/AML：转诊至国家级血液中心评估芦可替尼或移植可行性